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Research
Compared with bulk materials, nanoparticles 
(NPs) have unique and novel properties and 
thus offer great opportunities for develop-
ment of new industrial applications (Borm 
et al. 2006). Many NPs are already in use or 
have potential to be widely used in a range of 
applications (Nohynek et al. 2007). Maynard 
et al. (2006) and Nel et al. (2006) have called 
for risk assessment for the environment and 
humans before widespread industrial applica-
tion of NPs. Such risk assessment requires 
hazard identification and dose–response data.
In vitro assays have limitations and have 
not necessarily been validated for NPs (Kroll 
et al. 2009). In addition, the traditional 
mass dose does not well reflect the biologi-
cally effective dose for NPs, and surface area 
combined with surface reactivity is more 
likely a better descriptor of potential to cause 
inflammation at the site of particle deposition 
(Donaldson et al. 2008; Duffin et al. 2007; 
Tran et al. 2000).
The commonly proposed pathogenic 
mechanisms initiated by NPs are dominated 
by inflammation-driven effects, including 
fibrosis, oxidative stress, and DNA damage, 
making inflammation a target for toxico-
logical testing (Borm et al. 2006; Lu et al. 
2009; Nel et al. 2006, 2009). Inflammation 
is a complex, concerted group of responses 
that, although defensive against infection, is 
harmful when induced chronically by envi-
ronmental stimuli such as inhaled particles 
(Donaldson et al. 2006; Mroz et al. 2008; 
Oberdorster et al. 2005). The type, harm-
fulness, and outcome of inflammation vary 
depending on the nature of the stimulus ini-
tiating the inflammation; the affected tissue; 
the nature of the cellular exudates; its chro-
nicity, severity, and potential to resolve; and 
the genetic susceptibility of the individual.
Inflammation cannot be replicated by 
in vitro models because it depends on an intact 
vascular system and a huge assortment of cellu-
lar and humoral inter  actions. Although in vitro 
studies with NPs can claim to demonstrate 
“pro  inflammatory effects,” such studies cannot 
demonstrate anything more than a general indi-
cation that such articles are likely to elicit “some 
sort” of inflammation; they cannot predict the 
form of inflammation or its tempo, persistence, 
or tendency to resolve.
We studied the acute pulmonary tox-
icity of a large panel of NPs [cerium oxide 
(CeO2NP), titanium dioxide (TiO2NP), car-
bon black (CBNP), silicon dioxide (SiO2NP), 
nickel oxide (NiONP), zinc oxide (ZnONP), 
copper oxide (CuONP), and amine-modified 
polystyrene beads (Beads)] and found that four 
of them possessed significant acute inflam-
mogenicity: CeO2NP, NiONP, ZnONP, and 
CuONP. We went on to study these four NPs 
further and found very different patterns of 
inflammation (in terms of time), resolution, 
and cellular exudates with each of the four   
different particle types.
Materials and Methods
Characterization of NPs. We used a panel 
of eight NPs (CeO2NP, TiO2NP, CBNP, 
SiO2NP, NiONP, ZnONP, CuONP, and 
Beads) purchased from commercial sources, 
as noted in Table 1. These NPs are typical 
of those most commonly used in industry. 
The surface area of NPs [Brunauer-Emmett-
Teller (BET) method] was determined 
by ParticlesCIC Ltd. (Leeds, UK) using 
a Micromeritics TriStar 3000 analyzer 
(Micromeritics Ltd., Dunstable, Bedfordshire, 
UK). All exposures took place using NPs 
dispersed in rat serum. NP stock solution 
was prepared at 6,000 cm2/mL in distilled 
water and sonicated with a probe sonicator 
(Philip Harris Scientific, Lichfield, UK) to 
break up aggregates. Rat serum (final con-
centration, 5%) was added for dispersion. 
The stock solution of NPs was then diluted 
with phosphate-buffered saline (PBS) to 
the final concentration. The hydrodynamic 
size and zeta potential of the NPs were ana-
lyzed in PBS containing 5% rat serum with 
a Brookhaven 90Plus particle size analyzer 
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Ba c k g r o u n d: Metal oxide nanoparticles (NPs) have been widely used in industry, cosmetics, and 
biomedicine.
oBjectives: We examined hazards of several well-characterized high production volume NPs because 
of increasing concern about occupational exposure via inhalation.
Me t h o d s : A panel of well-characterized NPs [cerium oxide (CeO2NP), titanium dioxide 
(TiO2NP), carbon black (CBNP), silicon dioxide (SiO2NP), nickel oxide (NiONP), zinc oxide 
(ZnONP), copper oxide (CuONP), and amine-modified polystyrene beads] was instilled into lungs 
of rats. We evaluated the inflammation potencies of these NPs 24 hr and 4 weeks post  instillation. 
For NPs that caused significant inflammation at 24 hr, we then investigated the characteristics of 
the inflammation. All exposures were carried out at equal-surface-area doses.
re s u l t s: Only CeO2NP, NiONP, ZnONP, and CuONP were inflammogenic to the lungs of 
rats at the high doses used. Strikingly, each of these induced a unique inflammatory footprint both 
acutely (24 hr) and chronically (4 weeks). Acutely, patterns of neutrophil and eosinophil infil-
trates differed after CeO2NP, NiONP, ZnONP, and CuONP treatment. Chronic inflammatory 
responses also differed after 4 weeks, with neutrophilic, neutrophilic/lymphocytic, eosinophilic/
fibrotic/granulomatous, and fibrotic/granulomatous inflammation being caused respectively by 
CeO2NP, NiONP, ZnONP, and CuONP.
co n c l u s i o n: Different types of inflammation imply different hazards in terms of pathology, risks, 
and risk severity. In vitro testing could not have differentiated these complex hazard outcomes, 
and this has important implications for the global strategy for NP hazard assessment. Our results 
demonstrate that NPs cannot be viewed as a single hazard entity and that risk assessment should be 
performed separately and with caution for different NPs.
key w o r d s : eosinophilic inflammation, intratracheal instillation, in vitro assay, in vivo assay, lympho-
cytic inflammation, metal oxide nanoparticles, neutrophilic inflammation, risk assessment, surface area 
dose, Wistar rat. Environ Health Perspect 118:1699–1706 (2010).  doi:10.1289/ehp.1002201 [Online 
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(Brookhaven Instruments Corp., Holtsville, 
NY, USA) and a Zetasizer-Nano ZS instru-
ment (Malvern Instruments Ltd., Malvern 
Hills, UK), respectively. The levels of endo-
toxin in the NP suspension were evaluated by 
the Limulus amebocyte lysate assay (Cambrex 
Corp., Walkersville, MD, USA).
Intratracheal instillation of NPs and 
broncho  alveolar lavage. Female Wistar 
rats (200–250 g) obtained from Harlan 
Laboratories (Hillcrest, UK) were maintained 
and handled under a specific license granted 
by the UK Home Office to one of the authors 
(K.D.) that ensures humane treatment and 
alleviation of suffering in all animal experi-
ments. NPs dispersed in saline containing 5% 
rat serum were prepared at surface area doses of 
100 and 300 cm2/mL. The hydro  dynamic size 
of the particles, as instilled (Table 1), confirms 
that these were not singlet NPs but aggre-
gates whose size was well within the respirable 
size range (which is a requirement for studies 
on any inhalation hazard). For controls, we 
used non  treated (sham) rats and rats instilled 
with saline containing 5% rat serum (vehi-
cle) (n = 5 animals per group). Intratracheal 
instillation of NPs and lavages were performed 
using methods previously described by Lu 
et al. (2009). For 24-hr studies, we instilled 
eight NPs at doses of 50 and 150 cm2/rat. In 
addition, CeO2NP, NiONP, ZnONP, and 
CuONP, which were inflammo  genic at 24 hr, 
were used for chronic studies; chronic toxicity 
study was also performed at the same doses.
Effects of different dispersant on inflam-
mogenicity by ZnONP. To evaluate the serum 
effects on the inflammogenicity of ZnONP, 
the NPs were dispersed with rat serum, 
human serum, or broncho  alveolar lavage fluid 
(BALF). Then, the ZnONPs were instilled 
into rats at 150 cm2/rat for 24 hr and a differ-
ential cell count was performed on the BALF.
Preparation of BALF. BALF samples were 
prepared as described previously (Lu et al. 
2009). Briefly, 10,000 cells were centrifuged 
onto glass slides; cells were then fixed with 
methanol and stained using Diff-Quik. We 
measured lactate dehydrogenase (LDH) levels 
in BALF using the Cytotoxicity Detection Kit 
(Roche Diagnostics Ltd., Burgess Hill, UK) 
according to the manufacturer’s instructions. 
Data are expressed as fold change compared 
with the vehicle control. Concentration of total 
protein in BALF was measured using a bicin-
choninic acid (BCA) assay (Sigma-Aldrich, 
Gillingham, Dorset, UK) according to the 
manufacturer’s instructions. Tumor necro-
sis factor-α (TNF-α), interleukin (IL)-1β, 
macro  phage inflammatory protein-2 (MIP-2), 
eotaxin, and interferon-γ (IFN-γ), all from the 
Quantikine Kit (R&D Systems Europe Ltd., 
Abingdon, UK), and IL-13 from Invitrogen 
(Camarillo, CA, USA) were measured in non-
diluted BALF following the manu  facturers’ 
directions. 
Histology and immunohistochemistry. For 
histological analysis, lungs fixed with 10% 
neutral buffered formalin were embedded in 
paraffin, sectioned, and stained with hema-
toxylin and eosin (H&E). We performed 
picrosirius red (PSR) staining for analy-
sis of fibrosis. Briefly, sections were depar-
affinized and hydrated with distilled water 
for 10 min. Sections were stained with 0.1% 
PSR for 90 min and then dehydrated and 
mounted. Immuno  histo  chemi  cal staining for 
CD3 as a T-cell marker and CD45RA as a 
B-cell marker was performed in the lungs of 
NiONP at 4 weeks post  instillation on paraf-
fin sections. Endogenous peroxidase activity 
was quenched with 3% hydrogen peroxide 
at room temperature for 15 min. For antigen 
retrieval, Borg Decloaker (Biocare Medical 
Inc., Walnut Creek, CA, USA) was applied 
for 2 min. Slides were then blocked with nor-
mal goat serum, and anti-rat CD3 antibody or 
anti-rat CD45RA antibody (both from AbD 
Serotec, Oxford, UK) was applied at 1:100 
dilution. Slides were washed three times and 
incubated for 30 min at room temperature 
with anti-mouse IgG from the Envision kit 
(Dako, Cambridgeshire, UK). After slides 
were washed three times, diamino  benzidine 
substrate (Vector Laboratories, Peterborough, 
UK) was applied. 
Vector diagram. We used vector diagrams 
to show the different patterns of inflamma-
tion. Parameters were grouped by neutro-
philic [poly  morpho  nuclear leukocytes (PMN), 
MIP-2, and IL-1β], cytotoxic (LDH and total 
protein), eosinophilic (eosinophils, eotaxin, 
and IL-13), and lymphocytic (lymphocytes and 
IFN-γ) inflammation. A template for drawing 
vector diagrams was transferred from Microsoft 
Office Excel (version 2007; Microsoft UK, 
Reading, UK) to Adobe Photoshop (version 
CS3; Adobe Consulting, London, UK). All 
data were inserted into the diagrams in the 
units originally derived, as given in the figures 
and tables. Each vector was then drawn and 
colored using Adobe Photoshop. 
Statistical analysis. Data are expressed 
as mean ± SD (n = 4) and were analyzed 
with GraphPad InStat software (version 3; 
GraphPad Software, Inc., La Jolla, CA, USA). 
We used one-way analysis of variance with 
post hoc Tukey’s pairwise comparisons to 
compare each treatment group. The value of 
p < 0.05 was taken to be statistically significant.
Results
Characterization of NPs. The physico  chemical 
characteristics of the panel of eight NPs are 
summarized in Table 1. Hydrodynamic size 
showed that all NPs had small aggregates, 
but the hydrodynamic size of SiO2NP and 
ZnONP (~ 300 nm) was larger than that of 
the other NPs (~ 100 nm). All NPs except 
Beads were negatively charged.
Cytological analysis of the BALF. Twenty-
four hours. Total cells in BALF of rats 
exposed to CeO2NP, NiONP, or CuONP 
were significantly increased (Figure 1) com-
pared with vehicle controls. Total cells were 
also significantly higher in rats treated with 
150-cm2 versus 50-cm2 NiONP. The numbers 
of PMN in BALF were significantly higher 
than those in vehicle controls after exposure 
to CeO2NP, NiONP, ZnONP, or CuONP, 
but we saw a significant positive dose response 
only with NiONP. Eosinophils were signifi-
cantly increased in BALF of rats treated with 
ZnONP or CuONP. Other NPs did not 
increase the number of eosinophils in BALF.
Four weeks. Total cell numbers were sig-
nificantly higher after NiONP or ZnONP 
treatment compared with vehicle controls 
(Figure 2). PMN were significantly increased 
with CeO2NP or NiONP treatment, and 
lymphocytes were significantly increased in the 
Table 1. Characterization of the eight NPs.
Nominal chemistry CeO2NP TiO2NP CBNPa SiO2NP ZnONPb CuONPc NiONP Beadsc
Diameter (nm) 20–30 30–40 14 10 < 10  < 50 10–20 36
Surface area (m2/g)d 24.1 27.5 254 523.4 48.2 29 91.8 —
Mass (μg) per 150 cm2 625 545 59 25 310 515 163.5 94
Mass (μg) per 50 cm2 208 182 19.7 8.3 103 172 54.5 31.3
Hydrodynamic size (nm)e 88.1 ± 29.3 119.1 ± 39.6 78.0 ± 41.8 377.5 ± 170.2 306.3 ± 102.7 112.1 ± 17.3 92.5 ± 4.1 96.1 ± 11.8
Polydispersitye 0.148 ± 0.04 0.21 ± 0.07 0.18 ± 0.01 0.27 ± 0.05 0.27 ± 0.07 0.21 ± 0.03 0.21 ± 0.08 0.13 ± 0.02
Zeta potential (mV)e –32.4 ± 5.6 –28.5 ± 5.2 –25.0 ± 5.0 –12.9 ± 3.7 –27.1 ± 1.4 –26.7 ± 12.5 –26.0 ± 5.0 40.3 ± 8.5
Endotoxin (pg/mL)f ND ND ND ND ND ND ND ND
ND, not detectable. Values are mean ± SD from four independent experiments. All chemicals were provided by Nanostructural and Amorphous Materials Inc. (Houston, TX, USA) 
except where noted.
aFrom Evonik Degussa GmbH (Frankfurt, Germany). bFrom NanoScale Corporation (Manhattan, KS, USA). cFrom Sigma-Aldrich Co. Ltd. (Gillingham, Dorset, UK). dDetermined by ParticlesCIC 
Ltd. except for CuO, which was supplied by Sigma-Aldrich Co. Ltd. (Gillingham, Dorset, UK). eNPs were dispersed in PBS with 5% rat serum. fEndotoxin detection limit < 10 pg/mL. Unique inflammatory responses to different NPs
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NiONP treatment groups. In addition, eosino-
phils were still significantly present in BALF at 
4 weeks in the high-dose ZnONP group but 
not in the low-dose group. We observed giant 
cells, a marker for chronic granulomatous 
inflammation, in lungs after treatment with 
ZnONP or CuONP. Interestingly, the neutro-
philic inflammation caused by NiONP was 
much more severe at 4 weeks than at 24 hr. 
Low-dose NiONP recruited the same types 
of inflammatory cells in the BALF at 4 weeks 
after instillation as the high dose. We observed 
no significant increases in inflammatory cells 
4 weeks after treatment with CuONP.
LDH and total protein concentration in 
BALF. Twenty-four hours. LDH, a marker of 
cell death, and total protein, a marker of cell 
permeability, were significantly increased in 
BALF relative to vehicle controls 24 hr after 
treatment with CeO2NP, NiONP, ZnONP, 
or CuONP [see Supplemental Material, 
Figure 1 (doi:10.1289/ehp.1002201)]. These 
findings were paradoxical for ZnONP given 
that treatment was not associated with a very 
substantial leukocyte influx. We observed sig-
nificant positive dose responses for LDH and 
total protein levels after NiONP and ZnONP 
treatment. Protein concentration was signifi-
cantly higher and LDH concentration was sig-
nificantly lower for high-dose CuONP than 
for low-dose CuONP. Total protein and LDH 
levels were comparable between high- and low-
dose CeO2NP groups.
Four weeks. LDH was significantly 
increased over controls 4 weeks after treatment 
in the high-dose CeO2NP group and both 
NiONP groups [see Supplemental Material, 
Figure 2 (doi:10.1289/ehp.1002201)]. Total 
protein levels also were significantly increased 
in both NiONP treatment groups. In contrast, 
low-dose NiONP was not associated with sig-
nificant increases in LDH or total protein lev-
els 24 hr after instillation.
Histological analysis. Twenty-four 
hours. Consistent with the BALF cytology 
results, CeO2NP, NiONP, ZnONP, and 
CuONP induced inflammation in lung tis-
sues (Figure 3). CeO2NP and NiONP treat-
ments were associated with mild to moderate 
neutro  philic infiltration in alveoli and in peri-
bronchial and peri  vascular regions. ZnONP 
treatment was associated with mild neutro-
philic and severe eosinophilic inflammation 
in alveoli and peri  bronchial and peri  vascular 
regions, with moderate hemorrhage. CuONP 
treatment was associated with severe neutro-
philic and mild eosinophilic inflammation in 
alveoli and in peribronchial and perivascular 
regions, with mild hemorrhage and moderate 
type II cell hyperplasia. TiO2NP, SiO2NP, 
and Beads produced no detectable inflamma-
tion in the lung, whereas CBNP treatment 
was associated with mild peri  vascular neutro-
philic inflammation.
Four weeks. Histological analysis of lung 
sections obtained 4 weeks after NiONP 
installation showed lipo  proteinaceous mate-
rial in the alveolar spaces, foamy macro  phages 
(presumed to contain lipoprotein) in the alve-
olar spaces (Figure 4), and many organized 
lymphocyte aggregates in the peri  vascular and 
peri  bronchial interstitium that consisted of 
B cells and T cells [see Supplemental Material, 
Figure 3 (doi:10.1289/ehp.1002201)]. 
Interestingly, we did not observe giant cells 
and fibrosis—which are commonly associated 
with chronic inflammation—after NiONP 
treatment. CeO2NP induced minimal to mild 
neutrophilic inflammation and rare granu-
lomas in alveoli and interstitium (Figure 4; 
see also Supplemental Material, Figure 4). In 
contrast, ZnONP induced alveolar and inter-
stitial inflammatory cell infiltration, includ-
ing eosinophils, macrophages, and giant cells, 
with severe fibrotic lesions that were predomi-
nantly in collapsed and contracted alveoli. 
CuONP induced granulomatous inflamma-
tion in alveoli and also induced interstitial 
fibrosis that was less severe than that associ-
ated with ZnONP.
Figure 1. Differential cell counts and images of BALF cells from rats 24 hr after intratracheal instillation of 
NPs (50 or 150 cm2/rat). Number of (A) total cells, (B) PMN, and (C) eosinophils. (D) Photomicrographs of 
BALF cells (cytospin preparations stained with Diff-Quik) from rats treated with 150 cm2 NPs. Black arrows 
indicate macrophages; blue arrows, PMN; red arrows, eosinophils. Abbreviations: NS, not significant; VC, 
vehicle control. For A–C, data are mean ± SD (n = 4 per group). Each treatment group was compared with 
vehicle control for statistical significance, whereas high-dose groups were compared with low-dose group 
to evaluate dose dependency. 
*p < 0.05, **p < 0.01, and #p < 0.001.
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Measurement of proinflammatory media-
tors. To evaluate the cytokine profile under-
lying inflammation, we selected and measured 
representative inflammatory mediators for 
neutrophilic (TNF-α, IL-1β, and MIP-2), 
eosinophilic (eotaxin and IL-13), and lympho-
cytic (IFN-γ) inflammation in BALF.
Twenty-four hours. We observed no sig-
nificant difference in TNF-α or IFN-γ in any 
treatment group compared with the vehicle 
control (data not shown). IL-1β was signifi-
cantly increased in the high-dose CeO2NP, 
NiONP, and ZnONP and high- and low-dose 
CuONP treatment groups [Table 2; see also 
Supplemental Material, Figure 5 (doi:10.1289/
ehp.1002201)]. MIP-2 levels in BALF were 
significantly increased in the low- and high-
dose CeO2NP, NiONP, and CuONP groups, 
but MIP-2 was not increased with either dose 
of ZnONP. ZnONP treatment was associ-
ated with significant increases in eotaxin 
and IL-13, consistent with the severe acute 
eosinophilia observed after ZnONP treatment. 
CuONP treatment, which resulted in modest 
eosinophilia, was associated with significantly 
increased eotaxin only.
Four weeks. At 4 weeks after instillation, 
levels of MIP-2 were significantly increased 
in the high-dose CeO2NP group and both 
NiONP dose groups [see Supplemental 
Material, Figure 6 (doi:10.1289/ehp. 
1002201)]. Levels of IFN-γ were significantly 
increased after treatment with low- and high-
dose NiONP and high-dose ZnONP. In 
contrast to the increases in IL-1β and MIP-2 
observed after 24-hr treatment with CuONP, 
the levels of these cytokines 4 weeks after 
installation were not significantly different 
from vehicle controls.
Effects of dispersion media on eosinophil 
recruitment by ZnONP. To evaluate the 
effects of rat serum on the recruitment of 
eosinophils, we instilled ZnONP with several 
dispersants. After 24 hr, ZnONP treatment 
was associated with comparable numbers of 
eosinophils in BALF when dispersed using 
rat serum (5.95 ± 2.74, × 105), human 
serum (5.52 ± 1.45, × 105), and rat BALF 
(5.40 ± 1.57, × 105).
Discussion
We dispersed NPs in 5% rat serum using an 
equal-surface-area dose as the exposure metric 
and instilled mass doses ranging from 50 to 
1,250 μg, which are roughly comparable with 
the predicted alveolar retained mass of 50 μg 
that would result from 1 month of exposure 
to a 250-μg/m3 cloud of NPs with aerody-
namic diameter of 0.25 μm (consistent with 
typical NPs included in our study) according 
to the multiple-path particle dosimetry depo-
sition model (Cassee et al. 2002). No single 
characteristic, including zeta potential, clearly 
predicted the inflammogenic potency of the 
eight NPs.
Using the rat model, we found that four 
metal oxide NPs each induced a different type 
of inflammation characterized by different 
types of infiltrating cells, inflammatory media-
tors, time course, and cytotoxicity. The vector 
diagrams in Figure 5 show the “inflammatory 
footprints” of each NP 24 hr and 4 weeks 
after instillation. After 24 hr of exposure, 
CeO2NP and NiONP were associated with a 
Figure 2. Differential cell counts and images of BALF cells from rats 4 weeks after intratracheal instilla-
tion of NPs (50 or 150 cm2/rat). Number of (A) total cells, (B) PMN, (C) eosinophils, and (D) lymphocytes. 
(E) Photomicrographs of BALF cells (cytospin preparations stained with Diff-Quik) from rats treated with 
150 cm2 NP. Black arrows indicate macro  phages; blue arrows, PMN; red arrows, eosinophils; green 
arrows, lymphocytes; white arrows, giant cells. Abbreviations: NS, not significant; VC, vehicle control. For 
A–D, data are mean ± SD (n = 4 per group).
*p < 0.05, **p < 0.01, and #p < 0.001, compared with the vehicle control. 
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neutrophilic/mild cytotoxic pattern; ZnONP 
was associated with an eosinophilic/severe cyto-
toxic pattern; and CuONP was associated with 
a neutrophilic/eosinophilic/severe cytotoxic 
pattern. Four weeks after instillation, differ-
ences among NPs and from the 24-hr patterns 
were evident from the chronic inflammation 
patterns we observed, including a modest 
residual neutrophilic/mild cytotoxic inflam-
mation with CeO2NP; a greatly amplified 
immunological/severely cytotoxic inflamma-
tion with NiONP; and the almost total resolu-
tion of acute inflammation with CuONP. We 
also observed a modest residual eosinophilic/
immunological signal in BALF from ZnONP-
exposed rats after 4 weeks. 
It is important to note the contrast between 
the BALF results and the histology of the lung 
sections. Although the BALF inflammatory 
profile had waned dramatically by 4 weeks 
in both ZnONP- and CuONP-exposed rats, 
the histological assessments showed fibrosis 
in both cases, although the specific histologi-
cal pattern differed between the ZnONP and 
CuONP groups. In contrast, the inflamma-
tion in the NiONP group, which had ampli-
fied greatly between 24 hr and 4 weeks, was 
not associated with fibrosis, although alveo-
lar lipo  proteinosis was present indicating 
severe, ongoing epithelial injury. It is pos-
sible, even likely, that fibrosis could develop 
in the longer term in NiONP-exposed lungs, 
as documented in previous studies with NiO 
particles and NPs showing late-developing   
pulmonary fibrosis (Ogami et al. 2009; Ozaki 
et al. 2002). The histological lesions 24 hr and 
4 weeks after CeO2NP instillation were con-
sistent with BALF analysis (neutrophilic and 
mild cytotoxic inflammation) except for the 
rare granulomas present at 4 weeks, which 
seem to be associated with areas of high par-
ticle deposition. We used instillation in this 
Figure 3. Photomicrographs showing lung histology 24 hr after intratracheal instillation of NPs (150 cm2/
rat). Abbreviations: al, alveolus; br, bronchiole; v, blood vessel; VC, vehicle control. Instillation of CeO2NP, 
NiONP, ZnONP, and CuONP induced multifocal inflammatory cell infiltration in the alveoli, peribronchiolar, 
and perivascular regions. Tissues were stained with H&E; each panel is representative of lung lesions 
observed in the same treatment group in this study. Bars = 50 µm.
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Figure 4. Photomicrographs of H&E (histology) and PSR (fibrosis) stain-
ing of lungs from rats 4 weeks after treatment with NPs (150 cm2/rat). 
Abbreviations: al, alveolus; br, bronchiole; v, blood vessel; VC, vehicle control. 
Each panel is representative of lung lesions observed in the same treatment 
group in this study. Extremely rare small granulomas were observed in the 
CeO2NP–exposed lungs; see the example in Supplemental Material, Figure 4 
(doi:10.1289/ehp.1002201). PSR staining showed that ZnONP and CuONP 
induced severe collagen deposition, whereas CeO2NP and NiONP showed no 
response. Blue arrows indicate granulomatous inflammation; green arrows, 
lymphocyte aggregation. Cho et al.
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study as a substitute for inhalation; although 
instillation is known to produce a localized 
high dose and a high dose rate, it is a useful 
method for comparing responses to different 
particle types (Driscoll et al. 2000).
CeO2NP- and NiONP-induced neutro-
philic/mildly cytotoxic inflammation at 24 hr 
was associated with elevated IL-1β, MIP-2, and 
LDH in BALF, and both IL-1β and MIP-2 
are mediators of acute neutrophilic inflamma-
tion (Ulich et al. 1991; Wolpe et al. 1989). 
Four weeks after CeO2NP instillation, a mild 
neutrophilic/cytotoxic inflammation associ-
ated with modestly increased MIP-2 expression 
was still evident. CeO2NP has been used as a 
fuel additive for diesel engines (B. Park et al. 
2008), and in vitro studies have shown that 
CeO2NP increased production of reactive oxy-
gen species in A549 cells (Lin et al. 2006) and 
BEAS-2B cells (E.J. Park et al. 2008). In con-
trast, CeO2NP has been reported to be non-
inflammatory (Lu et al. 2009) after pulmonary 
instillation, or cytoprotective in vitro by means 
of scavenging free radicals or reactive oxygen 
Table 2. Summary of inflammatory mediators, LDH, and total protein in BALF 24 hr (acute) and 4 weeks (chronic) after instillation of high-dose (150 cm2/rat) metal 
oxide NPs into rat lung. 
BALF measure VC CeO2NP NiONP ZnONP CuONP
Acute 
IL-1β (pg/mL) 0 ± 0 16.3 ± 7.5* 69.0 ± 25.5# 17.0 ± 7.7* 60.2 ± 12.5#
MIP-2 (pg/mL) 0 ± 0 226 ± 177* 643.5 ± 130.4# 11.1 ± 14.5 599.1 ± 264.0#
Eotaxin (pg/mL) 0 ± 0 11.3 ± 10.7 2.9 ± 2.5 714.4 ± 415.9# 54.4 ± 29.1#
IL-13 (pg/mL) 1.4 ± 0.3 3.0 ± 2.2 1.2 ± 0.6 44.2 ± 31.2# 0.6 ± 0.7
IFN-γ (pg/mL) 2.0 ± 4.0 0.9 ± 1.8 0 ± 0 0 ± 0 0 ± 0
LDHa 1.0 ± 0.01 3.3 ± 0.1# 3.5 ± 0.2# 12.3 ± 3.0# 6.4 ± 0.8#
Total protein (mg/mL) 0.19 ± 0.03 0.48 ± 0.13** 0.42 ± 0.08* 2.62 ± 0.63# 2.81 ± 1.14#
Inflammation (BALF and 
histology)
None Neutrophilic/cytotoxic Neutrophilic/cytotoxic Eosinophilic/cytotoxic Neutrophilic/eosinophilic/ 
cytotoxic
Chronic 
IL-1β (pg/mL) 2.8 ± 1.4 8.4 ± 6.6 2.0 ± 2.3 0 ± 0 0 ± 0
MIP-2 (pg/mL) 8.2 ± 1.3 31.9 ± 10.2** 39.5 ± 9.0# 3.7 ± 3.3 7.3 ± 4.5
Eotaxin (pg/mL) 0 ± 0 0 ± 0 1.9 ± 1.4 0.2 ± 0.4 0 ± 0
IL-13 (pg/mL) 1.5 ± 1.2 1.2 ± 0.8 0.8 ± 0.9 1.8 ± 1.1 1.6 ± 0.4
IFN-γ (pg/mL) 0 ± 0 0.7 ± 1.3 34.8 ± 15.1# 11.4 ± 5.0** 0 ± 0
LDHa 1.0 ± 0.01 4.7 ± 2.4* 23.5 ± 1.9# 1.5 ± 0.6 1.3 ± 0.2
Total protein (mg/mL) 0.17 ± 0.07 0.42 ± 0.34 3.24 ± 0.39# 0.34 ± 0.01 0.37 ± 0.04
Inflammation (BALF and 
histology)
None Neutrophilic/cytotoxic Neutrophilic/ lymphocytic/
alveolar lipoproteinosis/cytotoxic
Eosinophilic/granulomatous/
fibrosis
Granulomatous/fibrosis
VC, vehicle control. Data are mean ± SD (n = 4 per group). For full LDH and total protein levels, see Supplemental Material, Figures 1 and 2 (doi:10.1289/ehp.1002201); for the full cytokine 
profile, see Supplemental Material, Figures 5 and 6. 
aLevels of LDH were expressed as fold changes compared with vehicle control. *p < 0.05, **p < 0.01, and #p < 0.001, compared with VC.
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Figure 5. Vector diagrams showing trends and types of acute (A) and chronic (B) inflammation after instillation of NPs (150 cm2/rat). The various inflammatory 
parameters are shown as vectors, where radial axes depict the relative magnitude of any vector quantity. By joining the vector quantities, a unique pattern is pro-
duced for any treatment. The left upper quadrant shows lymphocytic parameters (lymphocytes and IFN-γ); right upper quadrant, neutrophilic parameters (PMN, 
MIP-2, and IL-1β); lower right quadrant, cytotoxic parameters (LDH and total protein); and lower left quadrant, eosinophilic parameters (eosinophils, eotaxin, and 
IL-13). VC, vehicle control. In A (24 hr after instillation), CeO2NP and NiONP showed neutrophilic inflammation with mild cytotoxicity. ZnONP and CuONP, respec-
tively, showed eosinophilic inflammation with severe cytotoxicity and neutrophilic/eosinophilic inflammation with severe cytotoxicity to the lungs of rats. In B) 
(4 weeks after instillation), CeO2NP still showed neutrophilic/mild cytotoxic inflammation. In contrast, NiONP showed neutrophilic/lymphocytic inflammation with 
severe cytotoxicity, and ZnONP and CuONP showed eosinophilic inflammation without cytotoxicity and no inflammatory responses, respectively. Unique inflammatory responses to different NPs
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species (Hirst et al. 2009). The discrepancies 
between our findings in this study and those 
in previous studies might be due to improved 
dispersion in the present study, which greatly 
increases the surface area compared with aggre-
gated NPs (Monteiller et al. 2007).
NiONP induced chronic neutrophilic/
lymphocytic/severely cytotoxic inflamma-
tion 4 weeks after instillation accompanied by 
increased MIP-2, IFN-γ, and LDH in BALF 
(Table 2). At this time point, the alveo  lar lipo-
proteinosis evident in NiONP-exposed lungs 
was reflected in very high protein and LDH 
levels in the BALF. IFN-γ is linked with lym-
phocytic inflammation (Bradley et al. 1996). 
Consistent with our findings, increased lev-
els of neutrophils and macrophages have been 
observed from 3 days to 3 months after instil-
lation of agglomerated NiONP suspended in 
distilled water in a previous study using Wistar 
rats (Nishi et al. 2009; Ogami et al. 2009). 
However, Nishi et al. (2009) did not conclude 
that worsening inflammation was driven by a 
developing allergic response, as suggested by 
our findings. The difference in the two stud-
ies might be due to the dispersion of NPs 
because, in our previous study (Lu et al. 2009), 
we reported that intra  tracheal instillation of 
NiONP without dispersion into Wistar rats 
induced acute neutrophilic inflammation in 
the lungs. 
The eosinophilic/severely cytotoxic inflam-
mation seen with ZnONP in BALF at 24 hr 
was associated with very high levels of eotaxin, 
IL-13, and LDH (Table 2). Eotaxin and 
IL-13 are chemokines principally recruiting 
eosinophils, a component of the inflammatory 
exudates in asthmatic lung diseases (Conroy 
and Williams 2001; Wills-Karp 2004). The 
granulomatous/eosinophilic inflammation 
seen in ZnONP-exposed lungs at 4 weeks was 
associated with increased IFN-γ levels. Until 
now, a limited number of in vivo studies   
have been performed on the pulmonary toxic-
ity of ZnONP. Intratracheal instillation of both 
nanometer-size ZnO (50–70 nm) and microm-
eter-size ZnO (< 1,000 nm) in rats resulted 
in severe cyto  toxicity and neutrophilic (but 
not eosinophilic) inflammation that peaked 
at 24 hr and resolved by 4 weeks after instil-
lation (Sayes et al. 2007; Warheit et al. 2009). 
In our previous study (Lu et al. 2009), we 
instilled 90–210 nm ZnO particles and found 
PMN, but no eosinophils, in BALF at 24 hr. 
In the present study we focused on the cellular 
nature, types, and mechanism of inflamma-
tion with nanometer-size ZnO (< 10 nm). It 
is notable that, in a human subject, accidental 
exposure to ZnO induced metal fume fever 
that recruited high levels of eosinophils into 
BALF (Castet and Bouillard 1992).
In the present study, exposure to CuONP 
was associated with neutrophilic/eosinophilic/
severely cytotoxic inflammation and increased 
levels of IL-1β, MIP-2, eotaxin, and LDH in 
BALF 24 hr after instillation. The granuloma-
tous inflammation seen 4 weeks after CuONP 
exposure was not associated with any increase 
in the meas  ured cytokines or LDH. In a previ-
ous study (Yokohira et al. 2008), CuONP was 
also very cytotoxic and induced severe neutro-
philic and granulomatous inflammation when 
instilled into lungs of rats. 
The finding of eosinophils in the cellular 
exudates of rats exposed to two of the NPs 
used here was unexpected. The rats used in our 
study were from a reputable supplier (Harlan 
Laboratories), and we have not encountered 
eosinophils in the lavage of rats instilled with 
numerous other dusts (e.g., asbestos, coal mine 
dust, glass fibers, urban particulate matter) 
over 30 years. A search of PubMed (National 
Center for Biotechnology Information 2010) 
using the three terms “zinc,” “nanoparticle,” 
and “eosinophil” gave no hits, but there is one 
report of 25% eosinophils in the BALF of a 
human subject exposed accidentally to ZnO 
fume (Castet and Bouillard 1992).
In these experiments in the present study, 
we observed the eosinophilic responses when 
treatments were randomized across a group of 
rats, so it is unlikely to be explained by para-
sitic infections, especially because the rats were 
specific-pathogen free. In a separate experi-
ment, we used ZnONP from another sup-
plier, but these rats also showed eosinophilia 
in the BALF after 24 hr (data not shown). We 
found essentially the same extent of eosinophil 
influx when we used rat serum, human serum, 
or rat BALF as the dispersant, so we are con-
fident that eosinophil recruitment is due to 
the ZnONP and not related to the method of 
dispersal. However, because this finding is so 
striking and unusual, it needs to be indepen-
dently verified in other laboratories. 
Our results with the four metal oxide NPs 
(CeO2NP, NiONP, ZnONP, and CuONP) 
suggest that each of these may have its own 
unique inflammatory footprint. The effects 
could arise from the NPs themselves, from 
soluble ions released from them, or from 
both. We previously showed that there can 
be differences in toxicity between different 
NPs of the same putative composition derived 
from different vendors (Lu et al. 2009). Such 
hetero  geneity necessitates unique case-by-case 
hazard evalua  tion, risk assessment, and risk 
management. This would be especially true 
of CuONP and ZnONP, should our find-
ings of an eosinophilic type response be borne 
out in exposed humans. Eosinophils play a 
key role in mediating asthma and other aller-
gic conditions, and according to the World 
Health Organization (2010), 300 million 
individuals suffer from asthma globally. Some 
of these individuals are likely to be employed 
in workplaces where there is potential for NP 
exposure, which might result in recruitment 
of eosinophils to their lungs, greatly increasing 
their risk of asthma attacks.
There is a perceived need for rational 
toxicological (hazard) assessment of the large 
number of untested NPs and their variants 
(e.g., size, derivatization, composition), but 
there is also strong ethical and financial pres-
sure to carry out such toxicological testing 
using in vitro approaches. Our findings sound 
a note of caution regarding this approach and 
strongly support the utility of in vivo mod-
els, because the variability in inflammatory 
responses and resulting pathology could never 
have been predicted or detected by in vitro 
assays. Although conventional in vitro assays 
might have found the panel of NPs to have 
a pattern of toxic potency similar to what we 
observed in vivo, such assays would never have 
revealed the under  lying immuno  pathological 
mechanism, greatly enriching the hazard iden-
tification and hazard characterization of these 
materials (Clewell 2005). Other weaknesses of 
in vitro testing are well documented, includ-
ing use of single cell lines to mimic complex 
tissue, lack of blood supply, and high doses 
(Donaldson et al. 2009).
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